Philpott N, Mehta J, Treleaven J, Powles R
Department of Haematology, Royal Marsden Hospital, Sutton, Surrey, UK.
Leuk Lymphoma. 1994 Sep;15(1-2):127-30. doi: 10.3109/10428199409051686.
Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy. We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.
5例治疗相关性急性髓系白血病患者接受了去甲氧柔红霉素、大剂量阿糖胞苷和依托泊苷的联合诱导化疗。所有患者单疗程治疗后均达到完全缓解。治疗相关毒性包括恶心、呕吐、黏膜炎、腹泻以及肝肾功能异常，所有患者的毒性反应均较轻。诱导治疗期间无死亡病例。我们得出结论，该联合方案在继发性急性髓系白血病诱导缓解治疗中耐受性良好，且由于完全缓解率非常高，值得进一步评估。
